Allogene Highlights Potential For Cema-Cel In The Community Setting

CAR-T cells
Allogene announced results from an interim futility analysis of a Phase II study of cema-cel in first-line consolidation of LBCL. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cell Therapies

More from Cell & Gene Therapies